AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9804720 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 109
Study 7623755 — intervention group
Group type: EXPERIMENTAL
Intervention: Test site with Plaque Index (P1I) = 0
Number of subjects: 33
Study 7623755 — intervention group
Group type: COMPARATOR
Intervention: Control site with highest P1I score (2 or 3)
Number of subjects: 33
Study 7623755 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and control sites
Number of subjects: 33
Study 2695806 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg telenzepine once daily
Number of subjects: 120
Study 2695806 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg telenzepine once daily
Number of subjects: 120
Study 2695806 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg telenzepine once daily
Number of subjects: 120
Study 2695806 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg and 3 mg telenzepine
Number of subjects: 120
Study 780300 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 0
Study 780300 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 30952565 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care centres providing HIV testing, prevention, and treatment services.
Number of subjects: 23990
Study 30952565 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 23990
Study 30952565 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care centre exposure (visited at least once).
Number of subjects: 23990
Study 28592250 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass Testing and Treatment (MTaT) approach
Number of subjects: 10
Study 28592250 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 10
Study 25983237 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity (TPA)
Number of subjects: 54
Study 25983237 — intervention group
Group type: COMPARATOR
Intervention: Reference group (REF)
Number of subjects: 54
Study 23775515 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% diltiazem gel
Number of subjects: 62
Study 23775515 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 62
Study 21665103 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowen Technique
Number of subjects: 120
Study 21665103 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 19768381 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential intravenous/oral moxifloxacin, 400 mg once daily for 7-21 days
Number of subjects: 804
Study 19768381 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amoxicillin/clavulanate, 1,000 mg/200 mg three times daily followed by oral amoxicillin/clavulanate, 500 mg/125 mg three times daily for 7-21 days
Number of subjects: 804
Study 19768381 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential intravenous/oral moxifloxacin
Number of subjects: 804
Study 19768381 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amoxicillin/clavulanate followed by oral amoxicillin/clavulanate
Number of subjects: 804
Study 17074784 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 20
Study 17074784 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 20
Study 15322749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (15 mg/day)
Number of subjects: 5269
Study 15322749 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg/day)
Number of subjects: 5269
Study 15322749 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both ramipril and rosiglitazone)
Number of subjects: 5269
Study 11567764 — intervention group
Group type: EXPERIMENTAL
Intervention: PncD
Number of subjects: 50
Study 11567764 — intervention group
Group type: EXPERIMENTAL
Intervention: PncT
Number of subjects: 50
Study 11567764 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PncD and PncT
Number of subjects: 50
Study 9692107 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids treatment for 3 years
Number of subjects: 2147
Study 9692107 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 2147
Study 7843022 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of a transparent keratoscope during microsurgery
Number of subjects: 0
Study 7843022 — intervention group
Group type: COMPARATOR
Intervention: No application of a transparent keratoscope during microsurgery
Number of subjects: 0
Study 2848902 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-rhesus reassortant rotavirus vaccines (serotypes 1, 2, or 4)
Number of subjects: 0
Study 2848902 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-rhesus reassortant rotavirus vaccines (serotype 2)
Number of subjects: 0
Study 2848902 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 2848902 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-rhesus reassortant rotavirus vaccines
Number of subjects: 0
Study 31835278 — intervention group
Group type: EXPERIMENTAL
Intervention: Notification of patient nonadherence derived from real‐time claims data
Number of subjects: 2602
Study 31835278 — intervention group
Group type: EXPERIMENTAL
Intervention: Notification of patient nonadherence and pharmacist may contact patients by default
Number of subjects: 2602
Study 31835278 — intervention group
Group type: EXPERIMENTAL
Intervention: Notification of patient nonadherence and pharmacist may contact patients by physician choice
Number of subjects: 2602
Study 31835278 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2602
Study 31553979 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected ears of MD patients
Number of subjects: 30
Study 31553979 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral ears of MD patients
Number of subjects: 30
Study 31553979 — intervention group
Group type: COMPARATOR
Intervention: Control ears
Number of subjects: 30
Study 29075019 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 32
Study 29075019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 25561079 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour therapeutic play intervention
Number of subjects: 95
Study 25561079 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 95
Study 23685998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentacam densitometry measurements in MPS patients
Number of subjects: 65
Study 23685998 — intervention group
Group type: COMPARATOR
Intervention: Pentacam densitometry measurements in control subjects
Number of subjects: 65
Study 23685998 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal centre density values in MPS patients
Number of subjects: 65
Study 21145807 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ribavirin/day
Number of subjects: 71
Study 21145807 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg ribavirin/day
Number of subjects: 71
Study 21145807 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a/ribavirin treatment
Number of subjects: 71
Study 19026407 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (40 mg)
Number of subjects: 19
Study 19026407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16739539 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model based on age, race, and risk of IPV
Number of subjects: 305
Study 16739539 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model applied to validation dataset
Number of subjects: 305
Study 15215811 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 to 40 mg)
Number of subjects: 3408
Study 15215811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3408
Study 11294376 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on prescribing rates and problem-oriented educational outreach visits
Number of subjects: 40
Study 11294376 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study 9292674 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival cefuroxime not administered (n=9)
Number of subjects: 99
Study 9292674 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=90)
Number of subjects: 99
Study 8278160 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 0
Study 8278160 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0
Study 8278160 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 0
Study 3111689 — intervention group
Group type: EXPERIMENTAL
Intervention: Elantan Long (50 mg IS 5‐MN) daily for 12 months
Number of subjects: 38
Study 3111689 — intervention group
Group type: COMPARATOR
Intervention: Placebo phase
Number of subjects: 38
Study 28608523 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 50
Study 28608523 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 50
Study 27821027 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly intralesional triamcinolone injections
Number of subjects: 0
Study 27821027 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly intralesional triamcinolone injections
Number of subjects: 0
Study 24292559 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Illness Management and Recovery (I-IMR)
Number of subjects: 71
Study 24292559 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71
Study 22327761 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (chewing gum for mothers and chewable tablets for children, 3 times a day for 3 months)
Number of subjects: 60
Study 22327761 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (experimental group)
Number of subjects: 60
Study 22327761 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish (control group)
Number of subjects: 60
Study 20162736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Number of subjects: 811
Study 20162736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 10 mg
Number of subjects: 811
Study 20162736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 20 mg
Number of subjects: 811
Study 20162736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 811
Study 20162736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5-20 mg
Number of subjects: 811
Study 18176735 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (Dysport; 1000 mouse units (MU) divided between elbow, wrist and finger flexors)
Number of subjects: 40
Study 18176735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15660663 — intervention group
Group type: EXPERIMENTAL
Intervention: MOG gene polymorphisms (CA)n, (TAAA)n, C1334T, C10991T
Number of subjects: 111
Study 15660663 — intervention group
Group type: COMPARATOR
Intervention: Case-control analysis with healthy controls
Number of subjects: 111
Study 12550145 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 98
Study 12550145 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupressure
Number of subjects: 98
Study 12523328 — intervention group
Group type: COMPARATOR
Intervention: 1 g rectal paracetamol
Number of subjects: 24
Study 12523328 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg x kg(‐1) rectal paracetamol
Number of subjects: 24
Study 9798808 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg
Number of subjects: 14
Study 9798808 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 1 g
Number of subjects: 14
Study 7900626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 7900626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 1.0 mg/kg
Number of subjects: 93
Study 7900626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 1.5 mg/kg
Number of subjects: 93
Study 7900626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 1.5 mg/kg (open-label phase)
Number of subjects: 93
Study 7900626 — intervention group
Group type: COMPARATOR
Intervention: Placebo (AF group)
Number of subjects: 93
Study 7900626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 1.0 mg/kg (AF group)
Number of subjects: 93
Study 7900626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 1.5 mg/kg (AF group)
Number of subjects: 93
Study 7900626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 1.5 mg/kg (open-label phase, AF group)
Number of subjects: 93
Study 7900626 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (hypotension and dyspnea)
Number of subjects: 93
Study 2527133 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple daily insulin injections (three preprandial injections of short‐acting insulin (NovoPen) and once daily, bedtime extended‐acting insulin)
Number of subjects: 16
Study 2527133 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple daily insulin injections (NovoPen)
Number of subjects: 16
Study 781234 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen, 200 to 600 mg every six hours
Number of subjects: 0
Study 781234 — intervention group
Group type: COMPARATOR
Intervention: Aspirin, 325 to 975 mg every six hours
Number of subjects: 0
Study 781234 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen (long-term use)
Number of subjects: 0
Study 31647605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iscalimab (0.03, 0.1, 0.3, 1, or 3 mg/kg)
Number of subjects: 76
Study 31647605 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous iscalimab (3 mg/kg)
Number of subjects: 76
Study 31647605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iscalimab (10 or 30 mg/kg)
Number of subjects: 76
Study 31647605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iscalimab (3 mg/kg)
Number of subjects: 76
Study 31647605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iscalimab
Number of subjects: 76
Study 31647605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 29800080 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment (weekly lifestyle counseling and meal replacement diet)
Number of subjects: 170
Study 29800080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 170
Study 29800080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 28496044 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide (0.1 mol/kg)
Number of subjects: 102
Study 28496044 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate (0.1 mol/kg)
Number of subjects: 102
Study 26044516 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (2 g of powder containing 5 × 10^9 cfu of L. curvatus HY7601 and 5 × 10^9 cfu of L. plantarum KY1032 daily)
Number of subjects: 92
Study 26044516 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 92
Study 26044516 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 92
Study 23518872 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3602
Study 23518872 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin plus glycoprotein IIb/IIIa inhibitor
Number of subjects: 3602
Study 21681125 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane dressing
Number of subjects: 50
Study 21681125 — intervention group
Group type: COMPARATOR
Intervention: Aquacel dressing
Number of subjects: 50
Study 19029129 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 767
Study 19029129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 767
Study 16960523 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of soybean‐derived phosphatidylserine (S‐PtdSer), administered daily for 7 days prior to exercise and for 2 days following exercise
Number of subjects: 8
Study 16960523 — intervention group
Group type: COMPARATOR
Intervention: Glucose polymer placebo
Number of subjects: 8
Study 15331032 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated walking using a proprietary step-exercise device
Number of subjects: 4
Study 15331032 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional flying mode (depressing a keyboard key for continuous forward motion)
Number of subjects: 4
Study 15331032 — intervention group
Group type: COMPARATOR
Intervention: Passive observation of walking participants
Number of subjects: 4
Study 15331032 — intervention group
Group type: COMPARATOR
Intervention: Passive observation of flying participants
Number of subjects: 4
Study 10674516 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 60
Study 10674516 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1%
Number of subjects: 60
Study 10674516 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 2%
Number of subjects: 60
Study 10674516 — intervention group
Group type: COMPARATOR
Intervention: Control (no general anesthesia)
Number of subjects: 60
Study 10674516 — intervention group
Group type: COMPARATOR
Intervention: All groups (Ropivacaine 0.75%, Ropivacaine 1%, Mepivacaine 2%)
Number of subjects: 60
Study 9059093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.0 MAC‐h)
Number of subjects: 50
Study 9059093 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (1.5 MAC‐h)
Number of subjects: 50
Study 8103359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin adhesive glue
Number of subjects: 68
Study 8103359 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin adhesive)
Number of subjects: 68
Study 29652792 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue mussel diet (75 g blue mussels, five days a week)
Number of subjects: 39
Study 29652792 — intervention group
Group type: COMPARATOR
Intervention: Control diet (75 g meat, five days a week)
Number of subjects: 39
Study 27256357 — intervention group
Group type: EXPERIMENTAL
Intervention: ebselen (3600 mg over 24 h)
Number of subjects: 20
Study 27256357 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 25518523 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (Elkar, PikFarma)
Number of subjects: 0
Study 22858387 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (3 times/week for 4 months)
Number of subjects: 101
Study 22858387 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day for 4 months)
Number of subjects: 101
Study 22858387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 21184675 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with daily glutamine supplement of 0.35 g/kg
Number of subjects: 43
Study 21184675 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric-isonitrogenated TPN (Control)
Number of subjects: 43
Study 18702333 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐IFN‐alpha/RBV treatment (n = 18 with 2a, n = 9 with 2b)
Number of subjects: 47
Study 18702333 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 47
Study 18702333 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐IFN‐alpha/RBV treatment
Number of subjects: 47
Study 15912895 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive SaphLITE harvest
Number of subjects: 200
Study 15912895 — intervention group
Group type: COMPARATOR
Intervention: Traditional saphenous vein harvest
Number of subjects: 200
Study 12733733 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate, 10 mg/day plus calcium carbonate (600 mg daily)
Number of subjects: 195
Study 12733733 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple vitamin D (ergocalciferol, 30,000 IU weekly) plus calcium carbonate (600 mg daily)
Number of subjects: 195
Study 12733733 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol, 0.5 to 0.75 microg/day
Number of subjects: 195
Study 12733733 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 195
Study 10100105 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg once a day)
Number of subjects: 96
Study 10100105 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4-8 mg once a day)
Number of subjects: 96
Study 8626362 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 3500
Study 1725545 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem controlled-release (CR) 120 mg b.i.d.
Number of subjects: 56
Study 1725545 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 100 mg b.i.d.
Number of subjects: 56
Study 6401458 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent hormone treatment and cytotoxic chemotherapy
Number of subjects: 464
Study 6401458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential hormone treatment and cytotoxic chemotherapy
Number of subjects: 464
Study 6401458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential hormone treatment for postmenopausal women in the low-risk category
Number of subjects: 464
Study 31640763 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention of level IIb
Number of subjects: 522
Study 31640763 — intervention group
Group type: COMPARATOR
Intervention: Dissection of level IIb
Number of subjects: 522
Study 29438073 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week stroke self-management program
Number of subjects: 128
Study 29438073 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 128
Study 26897450 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST) for anxiety alleviation with anxiolytics
Number of subjects: 360
Study 26897450 — intervention group
Group type: EXPERIMENTAL
Intervention: Compact Disk Recording of Guided Imagery (CDRGI) with ST
Number of subjects: 360
Study 26897450 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with ST
Number of subjects: 360
Study 26897450 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual guided imagery with ST
Number of subjects: 360
Study 26897450 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology with ST
Number of subjects: 360
Study 26897450 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual guided imagery combined with reflexology with ST
Number of subjects: 360